Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Accured Expenses: 2015-2024

Historic Change in Accured Expenses for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$10.4 million.

  • Intellia Therapeutics' Change in Accured Expenses fell 111.50% to -$715,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.3 million, marking a year-over-year decrease of 95.04%. This contributed to the annual value of -$10.4 million for FY2024, which is 272.36% down from last year.
  • Per Intellia Therapeutics' latest filing, its Change in Accured Expenses stood at -$10.4 million for FY2024, which was down 272.36% from $6.0 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Change in Accured Expenses high stood at $17.3 million for FY2021, and its period low was -$10.4 million during FY2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $6.0 million (2023), whereas its average is $3.9 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Accured Expenses surged by 464.11% in 2020, and later slumped by 272.36% in 2024.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Change in Accured Expenses stood at $13.0 million in 2020, then soared by 32.45% to $17.3 million in 2021, then decreased by 7.74% to $15.9 million in 2022, then slumped by 62.17% to $6.0 million in 2023, then plummeted by 272.36% to -$10.4 million in 2024.